Ultragenyx Pharmaceutical Inc. | Mutual Funds
Mutual Funds that own Ultragenyx Pharmaceutical Inc.
American Funds Growth Fund of America
3,198,964
6.43%
233,269
0.15%
06/30/2018
American Funds New Perspective Fund
2,768,288
5.56%
0
0.28%
06/30/2018
American Funds Small Cap World Fund
1,775,970
3.57%
0
0.4%
06/30/2018
Hartford Mid Cap Fund
1,604,618
3.22%
-224,985
1.03%
07/31/2018
Fidelity Select Biotechnology Portfolio
1,433,037
2.88%
0
1.32%
07/31/2018
American Funds New Economy Fund
1,408,408
2.83%
0
0.62%
06/30/2018
Vanguard Small Cap Index Fund
1,189,521
2.39%
14,992
0.1%
07/31/2018
Vanguard Total Stock Market Index Fund
1,181,287
2.37%
1,104
0.01%
07/31/2018
T Rowe Price Health Sciences Fund
1,012,757
2.04%
194,041
0.67%
06/30/2018
iShares Russell 2000 ETF
997,612
2%
-534
0.17%
09/06/2018
| Address |
60 Leveroni Court
Novato California 94949
United States
|
|
Employees
|
- |
| Website |
http://www.ultragenyx.com |
| Updated |
07/08/2019 |
| Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. |
